Business case

Everything we do is based on a strong conviction that people are increasingly seeking alternatives that can eliminate, or alleviate pain without drugs, and thus almost without any side effects. Neurostimulation, which is our area of expertise, is such an alternative.

Global medtech companies also share this view and invest large sums in the neurostimulation/neuromodulation sector on a yearly basis, targeting a variety of different medical conditions. In 2024, the global market for neurostimulation products is expected to be worth around SEK 132.8 billion.

Our Treatment for Chronic Rhinitis and Migraine

Chronic rhinitis and migraine are the conditions we have chosen to focus on. Initially, Kinetic Oscillation Stimulation, K.O.S, was exclusively a treatment for rhinitis. Gradually, doctors discovered that many patients also experienced that their migraine symptoms improved. Therefore, we began to investigate exactly how K.O.S can be used against chronic migraine.

Both rhinitis and migraine affect a large number of people globally. Our treatment for chronic rhinitis is available in the Nordic countries, in selected markets in the EU, in Israel and Saudi Arabia. We are currently conducting important clinical trials in both of these therapy areas.

CE Marking

Chordate Medical’s K.O.S treatment has been CE-marked since May 2021 for the preventive treatment of chronic migraine in adults over the age of 18, and is sold in selected European markets and in Israel. In August 2021, the K.O.S treatment began to be used for the treatment of chronic migraine in regular clinical practice in Sweden.

The K.O.S method is also CE-marked for the treatment indication rhinitis, and the treatment is available in the Nordic countries, in selected markets in the EU, in Israel and Saudi Arabia.

Here you can read more about the clinical studies that have been conducted.

A clear Exit Strategy

Chordate Medical has a clear exit strategy. We have built our market capitalization on three pillars: a comprehensive patent portfolio, strong scientific evidence from clinical trials, and by demonstrating early sales achievements in a few selected markets.

CEO Anders Weilandt about Chordate’s plan for the future.

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

The information is handled according to our privacy policy